HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.1%

Neg 0% Neu 91.1% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.